Aby J. Mathew
CIK 1556355 · EVP & Chief Scientific Officer · last filed 2026-10-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BLFS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
#310
BOTHELL, WA 98021
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BIOLIFE SOLUTIONS INC (BLFS) Delisted | EVP & Chief Scientific Officer | 0 | $38.61 | $0 | -$20.87M | 142 | 2026-10-08 |
10b5-1 Trading Plans
3 plans| Company | Adopted | Sales Can Start | Ends | Plan Allows | Sold So Far | Status | Link |
|---|---|---|---|---|---|---|---|
| BLFS EVP & Chief Scientific Officer |
Jun 14, 2024 | Sep 12, 2024 | Jan 15, 2025 | -103,404 shares | 105,768 (-102%) last filed Jan 8, 2025 |
Ended | 10-Q |
| BLFS EVP & Chief Scientific Officer |
Mar 13, 2024 | Jun 11, 2024 | Dec 31, 2024 | -123,404 shares | 105,364 (-85%) last filed Dec 19, 2024 |
Ended | 10-Q |
| BLFS EVP & Chief Scientific Officer |
— | — | Ended Aug 17, 2023 | 263,404 shares | — | Ended early | 10-Q |
Recent Filings · Page 5 of 15
143 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-02-23 | BIOLIFE SOLUTIONS INC (BLFS) Delisted | Sell (S)10b5-1 | −101 | -$1.8K | EDGAR |
| 2024-01-23 | BIOLIFE SOLUTIONS INC (BLFS) Delisted | Sell (S)10b5-1 | −1,450 | -$24.3K | EDGAR |
| 2024-01-04 | BIOLIFE SOLUTIONS INC (BLFS) Delisted | Sell (S)10b5-1 | −697 | -$11.7K | EDGAR |
| 2023-12-21 | BIOLIFE SOLUTIONS INC (BLFS) Delisted | Grant (A) | +796 | $0 | EDGAR |
| 2023-12-19 | BIOLIFE SOLUTIONS INC (BLFS) Delisted | Grant (A) | +705 | $0 | EDGAR |
| 2023-12-04 | BIOLIFE SOLUTIONS INC (BLFS) Delisted | Mixed10b5-1 | +235 | -$7.3K | EDGAR |
| 2023-11-15 | BIOLIFE SOLUTIONS INC (BLFS) Delisted | Sell (S)10b5-1 | −132 | -$1.4K | EDGAR |
| 2023-11-13 | BIOLIFE SOLUTIONS INC (BLFS) Delisted | Grant (A) | +924 | $0 | EDGAR |
| 2023-10-24 | BIOLIFE SOLUTIONS INC (BLFS) Delisted | Grant (A) | +1,034 | $0 | EDGAR |
| 2023-10-10 | BIOLIFE SOLUTIONS INC (BLFS) Delisted | Grant (A) | +779 | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).